Top Abstract Purchase Related
Home
>
Node
>
Subnode

Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy

Platis, O.; Anagnostopoulos, G.; Farmaki, K.; Posantzis, M.; Gotsis, E.; Tolis, G.

Pediatric Endocrinology Reviews Per 2(Suppl 2): 279-281

2004

ISSN/ISBN: 1565-4753
PMID: 16462711
Document Number: 582157
Thalassaemic patients with haemocromatosis often present with metabolic disturbances such as diabetes mellitus. A group of adult thalassaemic patients who received intensive oral and subcutaneous chelation therapy (Defferiprone/Ferriprox and Desferioxamine/Desferal) for a period of 24-36 months was studied for the presence of glucose metabolism disturbances (GMD). Investigation of the prevalence of diabetes mellitus (DM) and impaired glucose tolerance (IGT) was carried out by yearly oral glucose tolerance tests (OGTT). Results showed that GMD (DM and IGT) improved in 1/3 of the patients after the intensive combined chelation treatment, a finding that we attributed to a reduction in liver iron deposits. Although this study is still in progress we believe that intensive combined chelation therapy may have a positive effect on glucose metabolism.

Document emailed within 1 workday
Secure & encrypted payments

Capra, L.; Atti, G.; De Sanctis, V.; Candini, G. 1983: Glucose tolerance and chelation therapy in patients with thalassaemia major Haematologica 68(1): 63-68
Kuppusamy, U.R.; Tan, J.A.M.A. 2011: Chelation therapy with desferrioxamine does not normalize ferritin level but attenuates oxidative damage and improves total antioxidant level in Malaysian Chinese beta-thalassaemia major patients West Indian Medical Journal 60(1): 3-8
Rodríguez Galindo, C.; Ortega Aramburu, J.J.; Alonso, J.L.; Albisu, M.; Casaldáliga, J.; Díaz de Heredia, C.; Olivé, T.; Bastida, P. 1994: Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major Medicina Clinica 102(19): 721-724
Gamberini, M.R.; Fortini, M.; De Sanctis, V.; Gilli, G.; Testa, M.R. 2004: Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center Pediatric Endocrinology Reviews: Per 2(Suppl 2): 285-291
De Sanctis, V.; Eleftheriou, A.; Malaventura, C. 2004: Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF) Pediatric Endocrinology Reviews: Per 2 Suppl. 2: 249-255
Ratzmann, K.P.; Witt, S.; Schulz, B.; Jahr, D.; Heinke, P. 1981: Effect of glibenclamide therapy on carbohydrate and lipid metabolism and insulin secretion in patients with glucose tolerance disorders : a 5-year study Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 36(23): 913-917
Maganga, E.; Smart, L.R.; Kalluvya, S.; Kataraihya, J.B.; Saleh, A.M.; Obeid, L.; Downs, J.A.; Fitzgerald, D.W.; Peck, R.N. 2015: Glucose Metabolism Disorders, HIV and Antiretroviral Therapy among Tanzanian Adults Plos one 10(8): E0134410
Lind, L.; Lithell, H. 1994: Impaired glucose and lipid metabolism seen in intensive care patients is related to severity of illness and survival Clinical Intensive Care: International Journal of Critical and Coronary Care Medicine 5(3): 100-105
Di Gregorio, F.; Leonardi, C.; Sciuto, C.; Cannella, A.; Pizzarelli, G. 1998: Intensive intravenous chelation in thalassemic patients with iron overload Minerva Pediatrica 50(3): 81-85
Tweve, E.N.; Kayabu, D.; Nassari, N.O.; Todd, J. 2015: Improvement in mortality and retention among adult HIV-infected patients in the first 12 months of antiretroviral therapy in Dodoma urban district, Tanzania Tropical Medicine and International Health: Tm and Ih 20(6): 791-796
Orlov, S.N.; AbramovVG 1988: Catheterization of the major vessels in intensive therapy of patients with surgical diseases of the abdominal organs Anesteziologiia i Reanimatologiia 1: 69-72
Zhang, J.; Shen, K.; Lang, J. 2002: Study on chemotherapy-induced disorders of glucose metabolism in patients with malignant ovarian tumor Zhonghua Fu Chan Ke Za Zhi 37(8): 481-483
Holzinger, U.; Feldbacher, M.; Bachlechner, A.; Kitzberger, R.; Fuhrmann, V.; Madl, C. 2008: Improvement of glucose control in the intensive care unit: an interdisciplinary collaboration study American Journal of Critical Care: An Official Publication American Association of Critical-Care Nurses 17(2): 150-156
Faruqi, A.; Ahmad, S.I.; Ahmed, S.T. 2016: Evaluation of QT parameters in patients of thalassaemia major with iron overload JPMA. Journal of the Pakistan Medical Association 66(7): 799-802
Rebulla, P.; Modell, B. 1991: Transfusion requirements and effects in patients with thalassaemia major. Cooleycare Programme Lancet 337(8736): 277-280
Skordis, N.; Ioannou, Y.S.; Kyriakou, A.; Savva, S.C.; Efstathiou, E.; Savvides, I.; Christou, S. 2008: Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major Pediatric Endocrinology Reviews: Per 6(Suppl 1): 144-148
Folstein, M.; Folstein, S.; McHugh, P.R. 1973: Clinical predictors of improvement after electroconvulsive therapy of patients with schizophrenia, neurotic reactions, and affective disorders Biological Psychiatry 7(2): 147-152
Riveline, B. 1975: 780SE in the management of disorders of lipid and glucose metabolism Postgraduate Medical Journal 51(Suppl 1): 162-164
Jończyk-Skórka, K.; Kowalski, J. 2017: The assessment of risk factors for glucose metabolism disorders Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 42(252): 241-246
Tolis, G.; Politis, C.; Kontopoulou, I.; Poulatzas, N.; Rigas, G.; Saridakis, C.; Athanasiou, V.; Mortoglou, A.; Malachtari, S.; Ling, N. 1987: Pituitary somatotropic and corticotropic function in patients with beta-thalassemia on iron chelation therapy Birth Defects Original Article Series 23(5a): 449-452